# ImmuXell Biotech

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/immuxell-biotech

- Industry: Biotechnology
- Headquarters: Shanghai, China
- Total disclosed funding: $14M
- Latest round: Series A (Oct 31, 2023)
- Investors on record: 3

## About

Established in 2021 and based in Shanghai, China, ImmuXell Biotech is a biotechnology company that focuses on providing tumor immune cell therapy services. As of 2023, the company's self-developed TCR-T cell therapy product targeting KRAS mutations completed an investigator-initiated clinical trial (IIT) for advanced pancreatic ductal adenocarcinoma, and is now in the IND filing preparation stage. In October 2023, it raised over CNY 100 million in series A funding led by new investor SDIC Venture Capital.

The company focuses on tumor immune cell therapy services. In addition, its main products are novel immune cell formulations targeting solid tumors.

The company will use the series A funding to accelerate the advancement of a novel TCR-T cell therapy product targeting the KRAS G12V mutation to apply for registration in clinical trials.

## Funding rounds

- Series A, Oct 31, 2023, $14M — SDIC Venture Capital, GSR United Capital, Huangpu Biomedical Investment

## Investors

- SDIC Venture Capital (https://capitalatlas.ai/funds/sdic-venture-capital) — Series A
- GSR United Capital (https://capitalatlas.ai/funds/gsr-united-capital) — Series A
- Huangpu Biomedical Investment (https://capitalatlas.ai/funds/huangpu-biomedical-investment) — Series A